Jubilant Pharmova announces completion of USFDA audit of Radiopharmaceuticals manufacturing facility at Montreal
The USFDA has issued 5 observations pursuant to the completion of audit
The USFDA has issued 5 observations pursuant to the completion of audit
Around 7% of the Indian population suffers from IBS
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
A five-day inspection was concluded successfully with no critical and no major observations raised
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The inspection was concluded with few procedural observations
The company will provide comprehensive response to USFDA for the observations
Cipla completes transfer of Generics Business Undertaking
Subscribe To Our Newsletter & Stay Updated